BIIB – biogen inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day BIIB SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
2/9/2026
04:06 pm
biib
biogen inc.
BEAT
-2.5%
2/6/2026
04:05 pm
biib
biogen inc.
BEAT
-3.7%
2/6/2026
06:19 am
biib
biogen inc.
BEAT
7.0%
10/31/2025
04:02 pm
biib
biogen inc.
BEAT
-1.8%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
Top News Decliners
10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
BIIB – biogen inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BIIB
SPY
QQQ
SPX
BIIB – biogen inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BIIB SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
4/20
10:47 am
biib
Low
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio [Yahoo! Finance]
4/20
07:51 am
biib
Medium
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region [Yahoo! Finance]
4/20
07:30 am
biib
Low
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
4/20
07:30 am
biib
Low
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
4/13
09:14 pm
biib
Low
Biogen (BIIB) was upgraded by Piper Sandler from "neutral" to "overweight".
4/13
01:18 pm
biib
Low
Biogen (BIIB) had its price target lowered by Truist Financial Corporation from $193.00 to $189.00. They now have a "hold" rating on the stock.
4/13
09:44 am
biib
Low
Biogen (BIIB) had its price target lowered by Citigroup Inc. from $215.00 to $190.00. They now have a "neutral" rating on the stock.
4/11
05:32 am
biib
Low
Biogen (BIIB) was upgraded by Argus to "hold".
4/10
10:23 am
biib
Low
Biogen (BIIB) had its price target raised by Morgan Stanley from $190.00 to $200.00. They now have an "equal weight" rating on the stock.
2/9/2026
04:06 pm
biib
-2.5%
BEAT
2/6/2026
04:05 pm
biib
-3.7%
BEAT
2/6/2026
06:19 am
biib
7.0%
BEAT
10/31/2025
04:02 pm
biib
-1.8%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
4/20
11:50 am
Upgrades
Equal-Weight
Overweight
Wells Fargo
Low
0.4%
4/20
11:50 am
Upgrades
Equal-Weight
Overweight
Wells Fargo
Low
0.4%
4/20
05:11 am
Upgrades
EQUAL WEIGHT
OVERWEIGHT
WELLS FARGO
Low
2.1%
4/20
05:11 am
Upgrades
EQUAL WEIGHT
OVERWEIGHT
WELLS FARGO
Low
2.1%
4/13
12:56 pm
Maintains
Neutral
Neutral
Citigroup
Low
1.9%
4/13
12:56 pm
Maintains
Neutral
Neutral
Citigroup
Low
1.9%
4/11
05:32 am
Upgrades
Hold
Argus
Low
1.8%
4/11
05:32 am
Upgrades
Hold
Argus
Low
1.8%
4/10
10:17 am
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
-0.6%
4/6
06:32 am
biib
Low
Form 8-K BIOGEN INC. For: Apr 06
4/3
04:06 pm
biib
Medium
Form 4 BIOGEN INC. For: Apr 01 Filed by: Godbout Sean
3/31
05:03 pm
biib
Low
Form 8-K BIOGEN INC. For: Mar 31
3/26
04:09 pm
biib
Medium
Form SCHEDULE 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
3/11
05:28 pm
biib
Low
Form 8-K BIOGEN INC. For: Mar 11
2/17
08:19 pm
biib
Low
Form 4 BIOGEN INC. For: Feb 13 Filed by: Viehbacher Christopher
2/17
08:18 pm
biib
Low
Form 4 BIOGEN INC. For: Feb 13 Filed by: Singhal Priya
2/17
08:17 pm
biib
Low
Form 4 BIOGEN INC. For: Feb 12 Filed by: Murphy Nicole
2/17
08:15 pm
biib
Low
Form 4 BIOGEN INC. For: Feb 13 Filed by: Kramer Robin
Show more
Top News Gainers
10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
Top News Decliners
10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%